Stockreport

Immuron Highlights Recent Milestones in Quest to Effectively Treat Multiple Forms of Fatty Liver Diseases That Impact Millions

Immuron Limited - American Depositary Shares  (IMRN) 
US:NASDAQ Investor Relations: immuron.com/investor-centre/business-overview
PDF Company’s lead drug candidate IMM-124E is well-positioned to pioneer successful treatment for NASH and NAFLD, diseases for which there is no proven effective treatment [Read more]